MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ('MIRA' or the 'Company'), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it will participate in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings planned as it explores potential licensing, strategic partnerships, and M&A opportunities.
The Company's lead candidate, Ketamir-2, a next-generation oral ketamine analog, is currently undergoing a Phase 1 clinical trial. With the second dosing cohort completed, the Company is now preparing to initiate the third cohort. Building on this momentum, MIRA anticipates initiating a Phase IIa study in neuropathic pain before the end of the year, advancing the development of what the Company believes could be a safe, effective non-opioid alternative for chronic pain management.
In addition, MIRA is advancing a series of preclinical studies with Ketamir-2, including models evaluating its potential in PTSD, as well as a topical formulation aimed at treating localized inflammatory pain. The Company is also finalizing regulatory filings related to its acquisition of SKNY Pharmaceuticals, Inc. ('SKNY'), with submission to the U.S. Securities and Exchange Commission (SEC) expected in the coming weeks. SKNY-1, SKNY's primary pharmaceutical candidate, is being developed as an oral therapeutic targeting smoking cessation and obesity, with activity at CB1, CB2, and MAO-B receptors.
'Our pipeline is advancing on all fronts, and we are focused on turning this scientific momentum into long-term value for patients and shareholders,' said Erez Aminov, Chief Executive Officer of MIRA. 'As we move closer to initiating Phase IIa and completing the SKNY transaction, we're actively exploring strategic opportunities to accelerate growth, including licensing and partnerships-especially in areas like chronic pain where non-opioid alternatives like Ketamir-2 are urgently needed.'
Dr. Angel, Chief Scientific Advisor at MIRA, added:
'We believe Ketamir-2 is paving the way for a new class of non-opioid therapies. The science is compelling, and the progress we have made is truly exciting. I look forward to sharing the depth of our work and the promising data we've generated with potential partners and investors.'
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
[email protected]
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
'I'm not here to pump up a stock': The hedge funder who sparked a speculative frenzy says he's not playing the meme stock game
Opendoor isn't a meme stock, says the hedge funder whose thesis sparked a huge rally in the shares. Eric Jackson, known for his call on Carvana in 2023, thinks Opendoor can rally more than 3,000%. He says Opendoor shouldn't be lumped together with other meme stocks that surged this week. The architect of the latest meme stock rally doesn't want you to call him that. Eric Jackson, the founder of EMJ Capital, is bullish on Opendoor—the online real estate platform that embarked on a blistering rally after he posted his thesis on X—but it isn't a meme stock, he says. In his eyes, it's the real deal, a pandemic-era darling with big turnaround potential despite a 92% tumble since its peak. Jackson is known for what ended up being a correctly bullish call on Carvana in 2023. He laid out his views on Opendoor on social media on July 14, sparking not only a rapid rise in the stock, which also seems to have revived the meme stock trade among a newer group of unloved stocks, including Kohl's, Krispy Kreme, and GoPro. But for Jackson, Opendoor isn't a joke. He declined to disclose the value of his firm's stake, but it's now the single biggest position in EMJ Capital's portfolio, he told Business Insider. "I never thought of it that way," he said of investors who called Opendoor a meme stock. "So I sort of take offense, because I find all the meme stocks to be, to me, kind of terrible businesses that I would never want to own. Whereas I see Opendoor as a legitimate turnaround story." Opendoor will probably be the only company among the meme-stock cohort that won't be forgotten about by next week, he said, adding that he sees the latest speculative buying spree fizzling out. Indeed, most of this week's meme stock cohort was already giving up their biggest gains by midday on Friday. Opendoor's stock price spiked as high as $4.97 this week in intraday trading, an almost 830% increase in July. The stock has since pared its gains, trading around $2.46 a share on Friday, but Jackson still thinks shares could hit $82 within the next several years, a gain that would mark a 3,200% increase from current levels. The next leg-up for the stock could come in the next few weeks when the company reports third-quarter earnings, Jackson said. 'I'm not here to pump up a stock' Opendoor first appeared on Jackson's radar in 2022, around the time he started paying attention to Carvana. In a podcast called "The Compound and Friends," he said he believed both companies, which were struggling at the time, could stage a massive turnaround. His bet on Carvana paid off. Shares of the online used car retailer have risen almost 7,000% since the beginning of 2023. The bet on Opendoor — until now — did not. The stock traded between $1-$3 a share around the time Jackson finally gave up on the call and cashed out his shares nine months ago. "It's like having a painful ex in your history and you just don't want to look at their Instagram page or something like that, because it just brings up bad feelings," he said. Jackson thinks the story could be different this time around for a few reasons: Opendoor stock now looks similar to Carvana when Jackson first made his call on the used car seller. Opendoor shares were trading under $1 around the time he fired off a series of posts about the company on X. Opendoor has aggressively slashed its costs in recent years. In 2024, it cut its workforce by 17%. The firm doesn't have much competition in the iBuying space now that Zillow and Redfin have exited that business. Opendoor was likely "thrown for a loop" by the Fed keeping interest rates higher for longer than expected in 2022 and 2023, Jackson said. High borrowing costs significantly impact the real estate sector, but most investors expect the central bank to cut rates several more times this year, potentially stimulating fresh activity in the housing market. Opendoor might also be able to benefit from a big AI play, Jackson told BI, citing conversations with a former company insider. Jackson says what he sees going for Opendoor sets it apart from the meme stocks at the center of this week's euphoric rally. "Does Kohl's have an AI strategy? Does American Eagle, other than hiring Sydney Sweeney, have an AI strategy? I mean, GoPro — I mean, come on," he said of the other meme stocks in the spotlight. On social media, Jackson frequently tells his followers he's on the quest to find the next "100-bagger," a term coined by the investor Chris Mayer to describe an investment that has the potential to return 100 times its value over the long run. Jackson's firm, which has also started leaning on AI models to identify stocks with glimmers of potential, tries to look for three things, he said: Have other people given up on the stock? Does it look substantially mispriced? Does it look like it has a sustainable turnaround trajectory? If the answers are "yes," it could be a winning trade, though he acknowledges the approach isn't an exact science. Successful investments Jackson has made that he deems as 100-baggers include Alibaba, Microsoft, Coinbase, and Roku, he said in a post on X in June. The Opendoor call, in particular, has garnered him a lot of attention. Speaking to Bloomberg, Jackson said his firm had received 600 calls or emails from people inquiring about his fund and investment ideas in the last several weeks. Since posting the Opendoor thread on X, he told BI he's spoken with investors all over Asia, Africa, Europe, and South America who buy into his call, but he has also come across "a lot of negative stuff" on X about his thesis. "I guess it comes with the territory when you stick your neck out there as a real person with real thoughts. You get all these anonymous trolls chirping back at you," he said. "I really hope that if all of retail and all institutional investors truly believe in this $82 story, my hope is they zero in with like, the Death Star on this planet, and just buy and hold," he said, adding that he believed investors could stage a rally similar to Cisco's meteoric rise during the dot-com bubble. Importantly, he emphasized that he's not a fan of people saying he sparked the meme stock rally. "But I'm some grifter or flipper, no. I'm in this for the long run. I'm not here to pump up a stock and jump out of it. I've never done that." Read the original article on Business Insider
Yahoo
8 minutes ago
- Yahoo
Aesthetic Partners Welcomes Healthcare Leader Mark Censoprano to Its Board Leadership Team
MIAMI, July 28, 2025 /PRNewswire/ -- Aesthetic Partners, a leading medical aesthetics and plastic surgery company, announced the appointment of Mark Censoprano as an Advisor to its Board of Directors. This strategic addition follows the appointment of industry veteran Brian Bouma to the Aesthetic Partners Board of Directors. The addition bolsters an already-robust team of industry veterans and high-caliber investors such as Norwest Venture Partners while further solidifying Aesthetic Partners' position as a leader in its field. Censoprano brings deep experience from a wide breadth of industries, including healthcare along with consumer brands. In addition to serving as Co-CEO of MAX Surgical Specialty Management, CEO of Guardian Dental Partners, and Chief Marketing Officer of Aspen Dental, Signet, and Sbarro, Censoprano has held board positions at WellHaven Pet Health and BonaDent Dental Laboratories and leadership roles at S.C. Johnson, Campbell Soup Company, and Darden Restaurants. "We are committed to being the best in medical aesthetics, and we lean on exceptional leaders from within and beyond our industry to achieve that," said Aesthetic Partners co-Founder and CEO Courtney Ellenbogen. "Mark brings executive experience from both healthcare and consumer brands along with a patient-focused perspective that we deeply value. He has already contributed so much to our team, and we look forward to strengthening our platform under his guidance." "I saw in Aesthetic Partners not only a leading brand in the industry, but a team that is doing it right", said Mark. "In a competitive market that has seen many new entrants, the AP team is not only a pioneer - they are also deeply committed to clinical quality, culture, and investing in talent. I am thrilled to be a part of their journey." Aesthetic Partners offers tailored support to its partner practices, which is a differentiated model within its category. That support includes access to industry leaders like Censoprano along with high-caliber training opportunities, strategic vendor relationships, growth capital, and practice expansion support. About Aesthetic Partners Aesthetic Partners is a leading medical aesthetics and plastic surgery company that partners with high-end, physician-led, and patient-centric practices. Aesthetic Partners provides growth capital, functional expertise, and new location expansion support to brands within its portfolio. Incubated at Harvard and founded in 2018, Aesthetic Partners is based in Miami, Florida, and is female- and minority-owned. For more information on Aesthetic Partners, visit For media inquiries, please contact press@ View original content to download multimedia: SOURCE Aesthetic Partners
Yahoo
8 minutes ago
- Yahoo
Ceva Logistics restructures North America operations, names new chief
Supply chain services giant Ceva Logistics has appointed Yves Laforgue, who joined the company last year through the acquisition of France-based Bolloré Logistics, as its new North America coordinator to better align regional operations with management's vision, according to an internal communication. CEO Mathieu Friedberg told employees in a memo on Friday that he is restructuring the North American organization, with Laforgue in charge, so it can capitalize on upcoming investments by parent company CMA CGM Group, and improve profit margins as it works to integrate Bolloré Logistics into its sprawling organization. Laforgue will continue his duties as CEO for Ceva Logistics Air & Ocean North America in addition to holding the new role. Ocean shipping giant CMA CGM, which acquired Ceva Logistics in 2019 and bought Bolloré Logistics in February 2024 for $5.2 billion as part of its transformation into a vertically integrated logistics services provider, announced in March that it would invest $20 billion over four years in U.S. ocean, air cargo and warehousing operations. Ceva Logistics is now the fifth largest global logistics service provider by gross revenue. 'In anticipation of these investments and to ensure that we are delivering on our three critical areas for success in 2025 — profitable growth, modernization and efficiency, and people — I have decided to reposition our NORTAM organizational structure and processes to enable greater efficiency, agility and cohesion,' Friedberg said in the message, which was obtained by FreightWaves. A Ceva employee, who spoke on condition of anonymity to avoid potential job retaliation, described operations on the ground as 'dysfunctional.' 'In his new role, Yves will focus on aligning and coordinating regional initiatives that span our products and functions. In addition, he will represent the company in front of public authorities and support our customers globally. His mandate is to simplify governance, accelerate decision making and make Ceva more agile and more responsive to the needs of our customers and our NORTAM teams on the ground,' Friedberg told staff members. 'We will accelerate in North America and need to create the right momentum and governance as close to the ground as possible. Alison Jahn, head of marketing and communications for Ceva North America, declined to comment on the organizational changes. Laforgue spent 30 years as an executive at Bolloré Logistics, including most recently as CEO of the Americas. Ceva has spent the past 18-months integrating Bolloré under its brand. Bolloré, which operated in 148 countries and employed 15,000 people, was a major air and ocean freight management company with additional capabilities in contract logistics, multimodal transportation, and e-commerce logistics. Ceva Logistics has continued to grow this decade through CMA CGM acquisitions of French automobile logistics provider GEFCO, Ingram Micro's e-commerce and lifestyle services business, and French last-mile delivery company Colis Privé Group. CMA CGM also launched its own all-cargo airline three years ago. Click here for more FreightWaves/American Shipper stories by Eric Kulisch. Write to Eric Kulisch at ekulisch@ RELATED STORIES: CMA CGM to invest $20B in US shipping, supply chain capabilities Ceva Logistics to acquire logistics provider in Turkey The post Ceva Logistics restructures North America operations, names new chief appeared first on FreightWaves. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
